CA2722706A1 - Di-t-butylphenyle piperazines utilisees comme inhibiteurs des canaux calciques - Google Patents

Di-t-butylphenyle piperazines utilisees comme inhibiteurs des canaux calciques Download PDF

Info

Publication number
CA2722706A1
CA2722706A1 CA2722706A CA2722706A CA2722706A1 CA 2722706 A1 CA2722706 A1 CA 2722706A1 CA 2722706 A CA2722706 A CA 2722706A CA 2722706 A CA2722706 A CA 2722706A CA 2722706 A1 CA2722706 A1 CA 2722706A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
alkenyl
alkynyl
heteroalkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2722706A
Other languages
English (en)
Inventor
Robert Galemmo Jr.
Gabriel Hum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceuticals Inc
Original Assignee
Zalicus Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zalicus Pharmaceuticals Ltd filed Critical Zalicus Pharmaceuticals Ltd
Publication of CA2722706A1 publication Critical patent/CA2722706A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2722706A 2008-04-28 2009-04-28 Di-t-butylphenyle piperazines utilisees comme inhibiteurs des canaux calciques Abandoned CA2722706A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4851708P 2008-04-28 2008-04-28
US61/048,517 2008-04-28
PCT/CA2009/000580 WO2009132454A1 (fr) 2008-04-28 2009-04-28 Di-t-butylphényle piperazines utilisées comme inhibiteurs des canaux calciques

Publications (1)

Publication Number Publication Date
CA2722706A1 true CA2722706A1 (fr) 2009-11-05

Family

ID=41215601

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2722706A Abandoned CA2722706A1 (fr) 2008-04-28 2009-04-28 Di-t-butylphenyle piperazines utilisees comme inhibiteurs des canaux calciques

Country Status (3)

Country Link
US (1) US20090270413A1 (fr)
CA (1) CA2722706A1 (fr)
WO (1) WO2009132454A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651811A1 (fr) * 2006-05-11 2007-11-22 Neuromed Pharmaceuticals Ltd. Methode d'augmentation de la biodisponibilite de composes contenant de la benzhydrylpiperazine
AU2010237750A1 (en) * 2009-04-16 2011-11-17 Takeda Pharmaceutical Company Limited Derivatives of N-acyl-N'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
GB201000685D0 (en) * 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
JP2014507424A (ja) 2011-03-08 2014-03-27 ザリカス ファーマスーティカルズ リミテッド 固体分散物製剤およびその使用方法
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
CN102526734A (zh) * 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
JP2014156442A (ja) * 2013-02-18 2014-08-28 Nippon Rikagaku Kogyo Kk アリールピペラジン誘導体又はその塩の製造方法
WO2014192865A1 (fr) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 Dérivé phénylpipérazine
EP3150598B1 (fr) 2014-05-28 2019-02-13 TOA Eiyo Ltd. Dérivés de tropane substitués
JP2018012645A (ja) * 2014-11-26 2018-01-25 持田製薬株式会社 新規ジアザビシクロ誘導体
AU2016341429B2 (en) 2015-10-22 2023-09-21 Cavion, Inc. Methods for treating Angelman Syndrome and related disorders
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
WO2018200850A1 (fr) 2017-04-26 2018-11-01 Cavion, Inc. Procédés d'amélioration de la mémoire et de la cognition, et de traitement des troubles de la mémoire et des troubles cognitifs
PL3487839T3 (pl) 2017-06-20 2021-06-14 Raqualia Pharma Inc. Pochodne amidowe jako blokery Nav1.7 i Nav1.8
JP7480131B2 (ja) 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
EP3996746A4 (fr) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. Formulations de modulateurs de canal calcique de type t et leurs procédés d'utilisation
JP2021070688A (ja) * 2019-10-24 2021-05-06 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906646A (en) * 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US5851824A (en) * 1988-04-04 1998-12-22 Sibia Neurosciences, Inc. Human calcium channel α-1C/α-1D, α-2, β-1, and γsubunits and cells expressing the DNA
US5876958A (en) * 1988-04-04 1999-03-02 Sibia Neurosciences, Inc. Assays of cells expressing human calcium channels containing α1 β subunits
CA1341170C (fr) * 1988-04-04 2001-01-16 Steven B. Ellis Structure des pores du calcium, et methodes pertinentes
US5846757A (en) * 1988-04-04 1998-12-08 Sibia Neurosciences, Inc. Human calcium channel α1, α2, and β subunits and assays using them
US5407820A (en) * 1988-04-04 1995-04-18 The Salk Institute Biotechnology/Industrial Associates, Inc. Calcium channel α-2 subunit DNAs and cells expressing them
US5386025A (en) * 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
US6096514A (en) * 1988-04-04 2000-08-01 Sibia Neurosciences, Inc. Human calcium channel compositions and methods
US5874236A (en) * 1988-04-04 1999-02-23 Sibia Neurosciences. Inc. DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits
US5670113A (en) * 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US20030125269A1 (en) * 1998-08-26 2003-07-03 Ming Li T-type calcium channel
IL141724A0 (en) * 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
KR100534556B1 (ko) * 2001-10-26 2005-12-08 주식회사 오리엔트바이오 알파１ｇ 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
GB0126781D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Modulation
EP1553946A4 (fr) * 2002-10-17 2008-07-16 Merck & Co Inc Amelioration du sommeil a l'aide d'antagonistes des canaux calciques de type t
EP1583821A4 (fr) * 2003-01-15 2007-07-18 Millennium Pharm Inc Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
JP2006522742A (ja) * 2003-04-08 2006-10-05 ニューロームド テクノロジーズ、インク． ピペラジンから距離をおいて配置したベンズヒドリル基から成る一群のカルシウムチャンネル阻害剤
CA2633457A1 (fr) * 2005-12-19 2007-06-28 Neuromed Pharmaceuticals Ltd. Derives d'amide heterocyclique en tant qu'inhibiteur calcique

Also Published As

Publication number Publication date
US20090270413A1 (en) 2009-10-29
WO2009132454A8 (fr) 2010-01-28
WO2009132454A1 (fr) 2009-11-05

Similar Documents

Publication Publication Date Title
US20090270413A1 (en) Di-t-butylphenyl piperazines as calcium channel blockers
US10351514B2 (en) Benzimidazole inhibitors of the sodium channel
US20090270394A1 (en) Cyclylamine derivatives as calcium channel blockers
US8629149B2 (en) Oxopiperazine derivatives for the treatment of pain and epilepsy
JP5560264B2 (ja) カルシウムチャネルブロッカーとしてのｎ−ピペリジニルアセトアミド誘導体
US20090298834A1 (en) 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
US20090012010A1 (en) Amino acid derivatives as calcium channel blockers
US20120220603A1 (en) Substituted heterocyclic derivatives for the treatment of pain and epilepsy
CA2663280A1 (fr) Composes de diaryle piperidine utilises en tant que bloqueurs de canaux calciques
US20100105682A1 (en) Cyclopropyl-piperazine compounds as calcium channel blockers
US11020391B2 (en) CRMP2 sumoylation inhibitors and uses thereof
US20090270338A1 (en) Diaryl-cyclylalkyl derivatives as calcium channel blockers
US20100029681A1 (en) Heterocyclic compounds as calcium channel blockers

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20130429